p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy

British Journal of Cancer

Volumn 82, Issue 2, 2000, Pages 392-398

  Ganly, I ^a,b,c   Soutar, D S ^a   Brown, R ^b   Kaye, S B ^b  

^a CANNIESBURN PLASTIC SURGERY UNIT   (United Kingdom)

^b Alexander Stone Building   (United Kingdom)

^c BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

Head and neck cancer; HPV; Mdm2; p53

Indexed keywords

PROTEIN P53; VIRUS DNA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; EXON; FEMALE; GENE DELETION; GENE INACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENT CANCER; SQUAMOUS CELL CARCINOMA; WART VIRUS;

EID: 0033979774     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.1999.0932     Document Type: Article

References (48)

1. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, et al (1996) A mutant adenovirus which selectively replicates in tumour cells with nonfunctional p53. Science 274: 373-376
2. Bottger A, Bottger V, Sparks A, Liu WL, Howard SF and Lane DP (1997) Design of a synthetic mdm2-binding mini protein that activates the p53 response in vivo. Curr Biol 7: 860-869
3. Boyle JO, Koch W, Hruban RH, van der Riet P and Sidransky D (1993) The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 53: 4477-4480
4. Brachman DG, Graves D, Vokes E, Beckett M, Haraf D, Montag A, et al. (1992) Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer. Cancer Res 52: 4832-4836
5. Buttitta F, Marchetti A, Gadducci A, Pellegrini S, Morganti M, Carnicelli V, et al. (1997) p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer 75: 230-235
6. Catimel G, Verweij J, Mattijssen V, Hanauske A, Piccart M, Wanders J, et al (1994) Docetaxel (taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 5: 533-537
7. Czegledy J, Iosif C, Hanson BG, Evander M, Gergely L and Wadell G (1995) Can a test for E6/E7 transcripts of human papillomavirus type 16 serve as a diagnostic tool for the detection of micrometastases in cervical cancer. Int J Cancer (Pred Oncol) 64: 211-215
8. Chung KY, Mukhopadhyay T, Kim J, Casson A, Ro JY, Goepfert H, et al (1993) Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract. Cancer Res 53: 1676-1683
9. Clavel M, Vermorken JB, Cognetti F, Cappelaere P, de Mulder PHM, Schornagel JH, et al (1994) Randomised comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil versus cisplatin in recurrent or metastatic squamous cell carcinoma of head and neck. Ann Oncol 5: 521-526
10. Clayman GL, El-Naggar AK, Roth JA, Zhang WW, Goepfert H, Taylor DL, et al (1995) In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 55: 1-6
11. Clayman GL, El-Naggar AK, Merritt J, Bruso P, Roth JA, Lippman S, et al (1998) Adenovirus mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 16: 2221-2232
12. Crook T, Wrede D and Vousden KH (1991) p53 point mutations in HPV negative human cervical carcinoma cell lines. Oncogene 6: 873-875
13. Cutilli T, Papola F, Di Emidio P, Leocata P and Corbacelli A (1998) p53 mutations and chemoresistance in oromaxillofacial squamous cell carcinomas. The results of a molecular genetics study of p53 in metastatic oromaxillofacial tumours and an evaluation of the response to neoadjuvant chemotherapeutic treatment. Minerva Stomatol 47: 1-9
14. Forastiere AA (1994) Overview of platinum chemotherapy in head and neck cancer. Semin Oncol 21: 20-27
15. Ganly I, Kirn D, Rodriguez GI, Soutar D, Eckhardt G, Otto R, et al (1997) Phase I trial of intratumoural injection with an E1B attenuated adenovirus, ONYX-015, in patients with recurrent p53(-) head and neck cancer. J Clin Oncol 16: 1362
16. Girod SC, Cesarz D, Fischer U and Krueger GR (1995) Detection of p53 and mdm2 protein expression in head and neck carcinogenesis. Anticancer Res 15: 1453-1457
17. Haraf DJ, Nodzenski E, Brachman D, Mick R, Montag A, Graves D, et al (1996) Human papilloma virus and p53 in head and neck cancer: clinical correlates and survival. Clin Cancer Res 2: 755-762
18. Haupt Y, Maya R, Kazaz A and Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299
19. Heise H, Sampson-Johannes A, Williams A, McCormack F, Von Hoff DD and Kirn DH (1997) Onyx-015, an E1B gene-attenuated adenovirus, causes tumour specific cytolysis and antitumuoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 3: 639-645
20. Huang LC, Clarkin KC and Wahl GM (1996) Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G1 arrest. Proc Natl Acad Sci USA 94: 4827-4832
21. Jones KR, Lodge-Rigal RD, Reddick RL, Tudor GE and Shockley WW (1992) Prognostic factors in the recurrence of stage I and II squamous cell cancer of the oral cavity. Arch Otolaryngol Head Neck Surg 118: 483-485
22. Kao CC, Yew PR and Berk AJ (1990) Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1B 55K proteins. Virology 179: 806-814
23. Koh JY, Cho NP, Kong G, Lee JD and Yoon K (1998) p53 mutations and human papilloma DNA in oral squamous cell cancer: correlation with apoptosis. Br J of Cancer 78: 354-359
24. Lechner MS (1992) Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. Embo J 11: 3045-3052
25. Levine AJ (1990) The p53 protein and its interactions with the oncogene products of the small DNA tumour viruses. Virology 177: 419-426
26. Liu TJ, Zhang WW, Taylor DL, Roth JA, Goepfert H and Clayman GL (1994) Growth suppression of human head and neck cancer cells by the introduction of a wild type p53 gene via a recombinant adenovirus. Cancer Res 54: 3662-3667
27. Liu TU, El-Nagger AK, McDonnell TJ, Steck KD, Wang M, Taylor DL, et al (1995) Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res 55: 117-122
28. Lowe SW, Riley HE, Jack T and Honsman DE (1993) p53 dependent apoptosis modulates the cytotoxicity of anticancer agents. Cancer Res 54: 3500-3505
29. Mao EJ, Schwartz SM, Daling JR, Oda D, Tickman L and Beckmann AM (1996) Human papilloma viruses and p53 mutations in normal pre-malignant and malignant oral epithelia. Int J Cancer 69: 152-158
30. Matsumura T, Yoshihama Y, Kimura T, Shintani S and Alcalde RE (1996) p53 and mdm2 expression in oral squamons cell carcinoma. Oncology 53: 308-312
31. McIlwrath AJ, Vasey PA, Ross GM and Brown R (1994) Cell cycle arrests and radiosensitivity of human tumour cell lines: dependence on wild type p53 for radiosensitivity. Cancer Res 54: 3718-3722
32. McKaig RG, Baric RS and Olshan AF (1998) Human papillomavirus and head and neck cancer: epidemiology and molecular biology. Head Neck 20: 250-265
33. Miguel RE, Villa LL, Cordeiro AC, Prado JC, Sobrinho JS and Kowalski LP (1998) Low prevalence of human papillomavirus in a geographic region with a high incidence of head and neck cancer. Am J Surg 176: 428-429
34. Nabel GJ, Nabel EG, Yang ZY, Fox BA, Plautz GE, Gao X, et al (1993) Direct gene transfer with DNA-liposome complexes in melanoma: expression, biological activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 90: 11307-11311
35. Nickers P, Kunkler I and Scalliet P (1997) Modern brachytherapy: current state and future prospects. Eur J Cancer 33: 1747-1751
36. Oliner JD, Kinzler KW, Meltzer PS, George D and Vogelstein B (1992) Amplification ofa gene encoding a p53 associated protein in human sarcomas. Nature 358: 80-83
37. Olshan AF, Weissler MC, Pei H and Conway K (1997) p53 mutations in head and neck cancer: new data and evaluation of mutational spectra. Cancer Epidemiol Biomarkers Prev 6: 499-504
38. Park T, Wilezynski SP, Paquette RL, Miller CW and Koeffer HP (1994) p53 mutations in HPV negative cervical carcinoma. Oncogene 9: 205-210
39. Paz IB, Cook N, Odom-Maryon T, Xie Y and Wilczynski SP (1997) Human papillomavirus (HPV) in head and neck cancer. An association of HPV16 with squamous cell carcinoma of Waldeyer's ring. Cancer 79: 595-604
40. Pruneri G, Pignataro L, Carboni N, Luminari S, Capaccio P, Neri A, et al (1997) Mdm2 oncoprotein overexpression in laryngeal squamous cell carcinoma: association with wild-type p53 accumulation. Mod Pathol 10: 785-792
41. Righetti SC, Torre GD, Pilotti S, Menard S, Ottone F, Colnaghi MA et al (1996) A comparitive study of p53 gene mutations, protein accumulation and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 56: 689-693
42. Roth JA (1996) Retrovirus mediated wild type p53 gene transfer to tumours of patients with lung cancer. Nature Med 2: 985-991
43. Scheffner M, Werness BA, Huibregtse JM, Levine AJ and Howley PM (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136
44. Stoler MM, Rhodes CR, Whitbeck A, Wolinsky SM, Chow LT and Broker TR (1992) Human papillomavirus type 16 and 18 gene expression in cervical neoplasms. Hum Pathol 23: 117-128
45. Snow GB (1989) Evaluation and staging of the patient with head and neck cancer. Churchill Livingstone, New York: 17-38
46. Yeudall WA and Campo MS (1991) Human papillomavirus DNA in biopsies of oral tissues. J Gen Virol 72: 173-176
47. Yoshikawa H, Kawana T, Kitagawa K, Mizuno M, Yoshikura H and Iwamoto A (1991) Detection and typing of multiple genital human papillomaviruses by DNA amplification with consensus primers. Jpn J Cancer Res 82: 524-531
48. zur Hausen H (1994) Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr Topics Microbiol Immunol 186: 131-156